1
TITLE: Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT) : a randomised, double-blind, placebo-controlled, phase 2 study  Full Text
AUTHORS: Wainberg, Zev A.; Enzinger, Peter C.; Kang, Yoon Koo; Qin, Shukui; Yamaguchi, Kensei; Kim, In Ho; Saeed, Anwaar; Oh, Sang Cheul; Li, Jin; Turk, Haci Mehmet; Teixeira, Alexandra; Borg, Christophe; Hitre, Erika; Udrea, Adrian A.; Cardellino, Giovanni Gerardo; Sanchez, Raquel Guardeno; Collins, Helen; Mitra, Siddhartha; Yang, Yingsi; Catenacci, Daniel V. T.; Lee, Keun Wook; ...More
PUBLISHED: 2022, SOURCE: LANCET ONCOLOGY, VOLUME: 23, ISSUE: 11
INDEXED IN: Scopus WOS
2
TITLE: Randomized double-blind placebo-controlled phase 2 study of bemarituzumab combined with modified FOLFOX6 (mFOLFOX6) in first-line (1L) treatment of advanced gastric/gastroesophageal junction adenocarcinoma (FIGHT).
AUTHORS: Wainberg, ZA; Enzinger, PC; Kang, YK; Yamaguchi, K; Qin, SK; Lee, KW; Oh, SC; Li, J; Turk, HM; Teixeira, AC; Cardellino, GG; Guardeno, R; Mitra, S; Yang, YS; Collins, H; Catenacci, DVT;
PUBLISHED: 2021, SOURCE: JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 39, ISSUE: 3
INDEXED IN: WOS